Plaque Psoriasis
Orismilast shows early efficacy in plaque psoriasis
The efficacy of orismilast is greater than placebo in patients with moderate to severe psoriasis, according to phase 2b trial results.
AX-158 receives clinical trial authorization for phase 2a psoriasis study in UK
AX-158 has received clinical trial authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for a phase 2a psoriasis study, Artax Biopharma announced in a press release.
Healio Minute Podcast, Dermatology Edition: Top Headlines - Week of October 30, 2023
In this edition, FDA approves Bimzelx for plaque psoriasis; roflumilast foam improves quality of life in patients with seborrheic dermatitis and more.
FDA approves Stelara biosimilar for treatment of psoriasis, multiple inflammatory diseases
The FDA has approved Wezlana as a Stelara biosimilar for the treatment of plaque psoriasis, psoriatic arthritis and other inflammatory diseases, according to an FDA press release.
Zoryve achieves plaque psoriasis improvement in 95% of patients
New phase 3 study data showed Zoryve cream 0.3% provided measurable improvement in psoriasis severity in nearly all treated individuals, Arcutis announced in a press release.
Tremfya efficacious in psoriasis in patients with skin of color
Tremfya showed fast and efficacious psoriasis clearance in patients with skin of color in a phase 3b trial, Jannsen announced in a press release.
Vtama cream 1% effective, safe for intertriginous plaque psoriasis treatment
New phase 4 study data showed Vtama cream 1% is effective and safe in the treatment of intertriginous plaque psoriasis in adults, Dermavant Sciences announced in a press release.
FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis
The FDA has approved Bimzelx for moderate to severe plaque psoriasis treatment in adults who are eligible for systemic therapy or phototherapy, UCB announced in a press release.
Data show Sotyktu maintains treatment outcomes for plaque psoriasis at 3 years
Three-year data from the POETYK PSO long-term extension trial of Sotyktu showed consistent efficacy and safety for the treatment of adults with moderate to severe plaque psoriasis, Bristol Myers Squibb announced in a press release.
Skyrizi achieves consistent results in plaque psoriasis across racial, ethnic groups
NEW YORK — Skyrizi exhibited efficacy across racial and ethnic groups for the treatment of moderate to severe plaque psoriasis, according to a presentation at the Skin of Color Update 2023 meeting.